Navigation Links
Tianyin Pharmaceutical Co., Inc. Announces Trading Symbol Error and Correction
Date:8/20/2008

CHENGDU, China, Aug. 20 /Xinhua-PRNewswire-FirstCall/ -- Tianyin Pharmaceutical, Co., Inc. (OTC Bulletin Board: TYNP, TYNPE), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced that the Company's stock symbol had been inadvertently changed to OTC BB: TYNPE due to the electronic eligibility system error.

The error is being corrected immediately and the Company expects the stock symbol to trade under the symbol OTC BB: TYNP on Thursday, August 21, 2008.

Tianyin Pharmaceutical Co., Inc. is a fully-reporting company and the Company's fiscal year ends on June 30. The Company will file its 10K for FY2008 on a timely manner, which is due on September 30. The Company has been compliant is all its fillings.

"This symbol error was very unfortunate and we do wish to assure our shareholders that there is absolutely no problem with Tianyin Pharmaceutical," said Dr. Jiang, Chairman and CEO of Tianyin Pharmaceutical Co., Inc. ''We will announce earnings results for fiscal year 2008 that ended June 30, 2008 before the reporting deadline of September 30, 2008. Additionally, we would like to reiterate that the Company expects to exceed its fiscal year 2008 make good of $5.6 million in net income or fully diluted EPS of $0.16 per share.''

About Tianyin Pharmaceuticals

Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine ("TCM") in China. It was established in 1994 and acquired by the current management team in August 2003. It has a comprehensive product portfolio of 34 modernized TCMs in the market, 22 of which are listed in the highly selective National Medicine Catalog of the National Medical Insurance Program. Tianyin owns and operates two GMP manufacturing facilities and an R&D platform supported by leading Chinese academic institutions. The Company has a pipeline of 51 pharmaceutical products pending approval. Tianyin has an extensive nationw
'/>"/>

SOURCE Tianyin Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Viscorp, Inc. Announces Name Change to Tianyin Pharmaceutical Co Inc. and Begins Trading Under the Ticker OTC BB: TYNP
2. Tianyin Pharmaceutical to Present at Roth Third Annual China Discovery Tour in Beijing on May 20, 2008 at 12:40 p.m. Beijing Time
3. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2008 Third Quarter Earnings Conference Call on Thursday, May 15, 2008 at 9:00 a.m. EDT
4. Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results
5. Tianyin Pharmaceutical Signs Over 60 New Distribution Agreements with 15 Regional Distributors
6. Tianyin Pharmaceutical Co., Inc. Completes Production for Earthquake
7. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Simvastatin Tablets
8. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
9. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
11. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2009)... NEW ORLEANSA new three-drug combination has shown in a ... "highly effective regimen" in the treatment of patients newly ... cells in bone marrow, say researchers from Dana-Farber Cancer ... all of the 66 patients treated with the drug ... a "very good partial response rate" in the phase ...
(Date:12/5/2009)... --In Youngest Babies, This Type of Blood Cancer Is ... Dec. 5 Pediatric oncologists have identified specific genes, ... drive an often-fatal form of leukemia in infants. By ... better predict which infants may benefit from particular treatments. ...
(Date:12/5/2009)... develop and test their cleaning processes. The technology available to the ... solve problems for customers relating to cleaning parts, process development, and ... ... Midbrook, Inc , a Jackson, MI-based company, is home to an ...
(Date:12/4/2009)... Calif., Dec. 4 Varian Medical Systems (NYSE: ... set the regular 2010 Annual Meeting of Stockholders for February ... The meeting will be held at the Crowne Plaza Cabana ... p.m. PT. ,, The meeting will be webcast by Thomson ...
(Date:12/4/2009)... Dec. 4 Allied World Assurance,Company Holdings, Ltd (NYSE: ... and Chief Executive Officer, and Jack Sennott, Executive Vice,President ... the 2009,Goldman Sachs U.S. Financial Services Conference being held ... on Tuesday, December 8, 2009. ,, ...
Breaking Medicine News(10 mins):Health News:Multiple myeloma patients experience high response rate with new 3-drug combination 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 3Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 4Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 2Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 3Health News:Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto 2Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2
... are the times when most people just don’t move ... as it helps them to fulfill psychological needs. ... a study and enquired from 1000 gamers their motivation ... Motivation and Emotion this month suggest that people enjoy ...
... various hospitals in New York are having a nice holiday ... ,The program is called Clown Care and believes in the ... Circus at New York-Presbyterian Hospital runs this program. It is ... and was introduced by Michael Christensen, co-founder of Big Apple ...
... in doubt. The mystery began Sept. 18, when a ... by a runny// nose, sneezing, slight fever, and mild cough ... last September through early November, about three dozen hospital employees ... that they, too, were stricken with the same disease. ...
... malnutrition. In spite of hospitalization the survival rate is less ... a research published concerning certain clinical signs that would indicate ... are at greater risk. ,The international group of researchers ... where 920 children were admitted with severe malnutrition between Septemb ...
... who have more children may have a shorter life span than ... mothers, says a new study.// ,Researchers led by Dustin Penn ... of 21,000 couples living in Utah between 1860 and 1985, who ... the couples had an average of eight children each, but family ...
... the hepatitis C virus turns on human immune defenses ... defenses by manipulating interaction of key cellular proteins, UT ... molecular “on/off switch” controls immunity against many viruses, highlighting ... viruses, the researchers report. ,In a study ...
Other Medicine News:Health News:Why People are Addicted to Video Games? 2Health News:Molecular ‘On/Off Switch’ Controls Immune Defenses Against Virus 2
(Date:12/4/2009)... Imaging, LLC, an independent provider of CT, MRI ... and healthcare providers, is excited to announce it ... Health Care, a nationally-recognized, prestigious gold seal of ... Shared Imaging accreditation is system-wide for its mobile ...
(Date:12/4/2009)... Hospira, Inc. (NYSE: HSP ), a leading ... the launch of its next-generation 50 mL and 100 ... and now offers a complete size range (50 mL ... product. The launch of the 50 mL and 100 ...
(Date:12/4/2009)... Suneva Medical, a privately-held aesthetic medical device company, ... President and Chief Financial Officer. In this role, ... administrative functions including finance, accounting, IT, IR, administration and ... Company,s senior management team. ,, "One of my ...
Breaking Medicine Technology:Shared Imaging Earns The Joint Commission's Accreditation for Ambulatory Health Care 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 3Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 4Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 2Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 3Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 4eCube Delivers Linux on System z Support for NXTera High Performance Middleware 62413 1eCube Delivers Linux on System z Support for NXTera High Performance Middleware 62413 2eCube Delivers Linux on System z Support for NXTera High Performance Middleware 62413 3Outpatient Disc Treatment Gives Long Term Back Pain Relief 62408 1Outpatient Disc Treatment Gives Long Term Back Pain Relief 62408 2Outpatient Disc Treatment Gives Long Term Back Pain Relief 62408 3AMT Announces Management Changes in Light of Refocused Strategy 6665 1AMT Announces Management Changes in Light of Refocused Strategy 6665 2AMT Announces Management Changes in Light of Refocused Strategy 6665 3
... Cougar Biotechnology,Inc. (OTCBB:CGRB) today announced that positive Phase ... cancer drug candidate CB7630,(abiraterone acetate) was presented at ... currently taking place,in Anaheim, California. The data was ... Research UK Centre for Cancer Therapeutics at,The Institute ...
... WIRE)--May 21, 2007 - Medical,professionals seeking to ... gram-negative pneumonia may have a new weapon:,NKTR-061 ... by Nektar Therapeutics (Nasdaq:NKTR)., Results of a ... of,NKTR-061 (Inhaled Amikacin) to treat mechanically ventilated,patients ...
Other Medicine Technology:Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at AUA Annual Meeting 2Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at AUA Annual Meeting 3Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at AUA Annual Meeting 4Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 2Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 3Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 4Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 5Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 6Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 7Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 8Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 9Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 10Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 11
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: